ASCO 2016 | Targeted therapy for advanced solid tumors based on molecular profiles: early results from MyPathway
Press brief by John Hainsworth, MD of the Sarah Cannon Research Institute, Nashville, TN, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Get great new content delivered to your inboxSign up
TTFields as an anti-mitotic therapy
The LUNAR study: TTFields for treating NSCLC
The STELLAR study: TTFields for malignant pleural mesothelioma
Afatinib for advanced EGFRm-positive NSCLC
TKIs to treat EGFRm-positive NSCLC